Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer
Table 2
First-line drug therapies and median overall survival (OS) times with respective 95% confidence intervals (CIs).